CannaCure Florida, a patient-focused producer of medical cannabis and related products, will host physicians and medical professionals for a peer-to-peer medical cannabis educational conference Nov. 18 in Tampa to provide guidance for incorporating medical cannabis into traditional medical practices. The event will be held 9 a.m. to 4:30 p.m. at the Cuban…
Researchers have discovered that a type of immune molecule — called “spliced epitopes,” once believed to be very rare — in fact makes up a large part of the molecules labeling cells as belonging to the body, and those that are invaders. The finding may well change our understanding of multiple…
A genome-wide analysis of over 110,000 people allowed researchers with the International Multiple Sclerosis Genetics Consortium (IMSGC) to discover 200 genetic loci (the position of genes on a chromosome) that are common to people with multiple sclerosis (MS). The findings were given in the presentation, “200 loci complete the genetic puzzle of multiple sclerosis,” by Dr. Nikolaos…
RedHill Biopharma recently announced that it has received a Notice of Allowance from the Japan Patent Office for a new patent covering RHB-104 as a potential treatment of multiple sclerosis (MS). Once granted, the patent will be valid until 2032. The European Patent Office also recently approved a patent application for the drug with this…
Apitope and Merck KGaA announced that they have entered into an exclusive agreement regarding ATX-MS-1467, a potential disease-modifying therapy for multiple sclerosis (MS). Under its terms, Apitope will regain full global rights over ATX-MS-1467, as well as all clinical data related to the compound. In 2009, the company granted exclusive global rights to Merck KGaA to develop…
Using a computer mouse can be difficult for people with the many diseases or injuries that affect muscular control, including those with multiple sclerosis (MS). So a company called Perceptive Devices has designed a way around that problem, and recently released a new version of its Smyle Mouse, a device that tracks facial…
The MS Society in the United Kingdom awarded £177,930 (about $217,800) to Dr. Sassan Hafizi, a researcher at University of Portsmouth, to investigate the potentially beneficial role of a central nervous system molecule, called Gas6, in repairing the myelin damage seen in patients with multiple sclerosis (MS) . Hafizi and Dr. Arthur…
Lemtrada (alemtuzumab) was seen to help reverse disability among patients with relapsing forms of multiple sclerosis (MS) in relatively early stages of the disease, researchers report. The study, “Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients,” published in the journal Neurology, supports the idea that treatment…
The National Multiple Sclerosis Society announced that is investing more than $10.5 million to support an anticipated 42 new research projects into multiple sclerosis (MS), part of its commitment to scientific efforts aimed at stopping MS, restoring lost function to patients, and, ultimately, ending the disease forever. The dedicated funding is part of a projected society investment of…
Mouse experiments with compounds having opposite actions on two receptors for TNF (tumor necrosis factor) — a key factor in neurodegeneration — explains why earlier trials of TNF blockers in multiple sclerosis (MS) went wrong, and paves the way for more selective drugs targeting the system to stop MS neurodegeneration. The…
Voluntary running triggers a molecule called VGF, a nerve growth factor, that was seen to induce a brain repair mechanism in animals, researchers at The Ottawa Hospital and the University of Ottawa in Canada report. The findings have important implications for multiple sclerosis (MS) and other conditions caused by damage to…
The MS Society in the United Kingdom is funding a new project at the University of Glasgow, in Scotland, to examine if heparin, a drug widely used for stroke patients, can repair neurological damage in people with multiple sclerosis (MS). MS is a progressive, debilitating, immune-mediated, neurodegenerative disorder in which…
Neurologists in the U.S. expect — or, at least, highly anticipate — that Ocrevus (ocrelizumab), being developed by Roche as a treatment for both relapsing and progressive multiple sclerosis (MS), will be approved by year’s end, and a sizable number plan on quickly prescribing it, according to a recent update by Spherix…
Disability from multiple sclerosis develops, on average, within 10 years of diagnosis. Financial catastrophe was often the consequence, until Congress passed the Achieving a Better Life Experience Act (ABLE Act) — signed into law on Dec. 19, 2014, by President Obama. This act allows you or anyone to…
Singer-songwriter Lori Jenaire is supporting the American Autoimmune Related Diseases Association (AARDA) #25for25 fundraising campaign with the release of her Top Five Billboard Hot Singles Sales debut “As You Are,” featuring Patrice Rushen. The song is a remake of the 1978 Pharoah Sanders’ R&B soul classic, which in its original version featured Phyllis…
The U.S. Food and Drug Administration (FDA) approved for marketing Adapta Medical’s PerfIC Cath, an intermittent and easy-to-use urinary catheter that was designed for patients with limited dexterity by a doctor who is also a quadriplegic. Urinary tract symptoms can trouble people with multiple sclerosis (MS). In fact, according to the National MS Society,…
GeneFo, an MS patient community that provides support, advice, and clinical trial matching, recently co-hosted an online conference with Trent Austin, MD, who reviewed the most updated research and clinical evidence of natural substances – including medicinal mushrooms, vitamins, biotin and cannabinoids – to inform the public about the potential…
Abide Therapeutics announced that Celgene has opted to obtain the rights, outside of the United States, to ABX-1431, Abide’s endocannabinoid system modulator being developed to treat neurological diseases, including multiple sclerosis (MS), by reproducing within the body the physical benefits (minus the psychotropic effects) of cannabis. ABX-1431 is an…
PathMaker Neurosystems is the winner of the Universal Biotech Innovation Prize 2016 for its innovative, non-invasive neurotherapy technologies to treat conditions linked to neural pathway disruption, including multiple sclerosis (MS). The selection was announced at Innovation Days, an international event honoring the best in the life sciences and held in Paris on Oct. 3–4. Launched in 2009 by a…
The Multiple Sclerosis (MS) Trust is expressing its disappointment at the recent committee decision of the National Institute for Health and Care Excellence (NICE) to not recommend Zinbryta (daclizumab) be made available as a therapy to MS patients using the public health system in England and Wales. NICE’s preliminary recommendation was based on a review of…
A researcher at De Montfort University Leicester (DMU)’s School of Nursing and Midwifery found that the practice of mindfulness helps people with long-term medical conditions, such as multiple sclerosis, to manage their diagnosis. The study, “Starting where I am: a grounded theory exploration of mindfulness as a facilitator…
The National Institute for Health and Care Excellence (NICE), the health authority for England and Wales, has decided not to recommend Zinbryta (daclizumab) be made available to multiple sclerosis (MS) patients through the country’s health service. The decision came in a first stage of the drug’s review process, and NICE is welcoming…
In a large prospective study with validated measures of physical activity, researchers found no evidence that exercise reduced a woman’s risk of developing multiple sclerosis (MS). Although physical activity is known to have numerous health benefits, it seems unlikely to protect a person against the likelihood of developing MS, the study concludes. The study, published…
Actelion announced that it will investigate the therapeutic potential of a new, oral combination therapy with ponesimod and Tecfidera (dimethyl fumarate) as a treatment for relapsing multiple sclerosis (RMS). The Phase 3 clinical study, being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA), aims to find…
In multiple sclerosis (MS), scientists have long believed that the body’s own immune system attacked myelin sheaths, the “insulating tape” that surrounds neurons, causing the disease. But researchers at Tel Aviv University are challenging that view, in a study reporting that MS may in fact be triggered by an instability inherent in the myelin membranes. The…
The National Multiple Sclerosis Society has launched an initiative, called Make MS Medications Accessible, calling for change in the pricing of multiple sclerosis (MS) medications in the U.S., which the group said need to be more affordable, and ways of acquiring them more simple and transparent. The initiative asks leaders of all…
In its effort to end progressive multiple sclerosis (MS), the International Progressive MS Alliance (PMSA) has awarded a $6.1 million grant to fund a research project led by Dr. Douglas Arnold with the Montreal Neurological Institute Hospital (MNI) at McGill University. The multiyear grant is one of three…
Antioxidant-filled nanoparticles injected under the skin may become a future multiple sclerosis (MS) treatment that comes with a perk or a drawback, depending on how a patient sees it. The injection leaves a temporary dark spot on the skin, resembling a tattoo. The tattoo might be a small issue considering…
How the multiple sclerosis (MS) therapy Tecfidera (dimethyl fumarate) works on a molecular level has finally been uncovered, using a new method that can map a drug’s protein targets. The insights gained may open up new avenues for the development of more specific drugs, based on the same mechanisms, but with fewer side effects. The study,…
Active Biotech acknowledged in an update on laquinimod, the oral small molecule being developed by Teva Pharmaceutical Industries to treat multiple sclerosis (MS) and Huntington’s disease (HD), that the U.S. Food and Drug Administration (FDA) has rescinded the special protocol assessment given to a Phase 3 study of the treatment in…
Get regular updates to your inbox.